Dyfrig Hughes

Summary

Country: UK

Publications

  1. Holmes E, Harris S, Hughes A, Craine N, Hughes D. Cost-Effectiveness Analysis of the Use of Point-of-Care C-Reactive Protein Testing to Reduce Antibiotic Prescribing in Primary Care. Antibiotics (Basel). 2018;7: pubmed publisher
    ..The implications for antibiotic resistance and Clostridium difficile infection warrant further investigation. ..
  2. Hill McManus D, Marshall S, Soto E, Lane S, Hughes D. Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model. Value Health. 2018;21:1373-1381 pubmed publisher
    ..The estimated value-based prices of lesinurad only exceeded that which has been proposed in the United Kingdom when assuming both perfect drug adherence and the eradication of gout flares in sustained treatment responders. ..
  3. Moore A, Young C, Hughes D. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease. Value Health. 2018;21:1322-1329 pubmed publisher
    ..This analysis demonstrates that the ALSFRS-R can be used to estimate EQ-5D-5L utilities when they have not been collected directly within a trial. ..
  4. Hughes D, Culeddu G, Plumpton C, Wood E, Dick A, Jones A, et al. Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis. Ophthalmology. 2018;: pubmed publisher
    ..Adalimumab is clinically effective in uveitis associated with JIA; however, its cost effectiveness is not demonstrated compared with methotrexate alone in the United Kingdom setting. ..
  5. Bourke S, Plumpton C, Hughes D. Societal Preferences for Funding Orphan Drugs in the United Kingdom: An Application of Person Trade-Off and Discrete Choice Experiment Methods. Value Health. 2018;21:538-546 pubmed publisher
    ..This has implications regarding the appropriateness of operating higher thresholds of cost-effectiveness. ..
  6. Hughes D, Ferner R. New drugs for old: disinvestment and NICE. BMJ. 2010;340:c572 pubmed publisher
  7. Hughes D, Dubois D. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. Pharmacoeconomics. 2004;22:1047-59 pubmed
    ..Oxy-IR, Oxy-XL and Tol-ER appear to be cost-effective options for the management of urge incontinence from the NHS perspective. A decision among the treatments depends on the acceptable cost per additional incontinent-free week. ..
  8. Morrison V, Holmes E, Parveen S, Plumpton C, Clyne W, De Geest S, et al. Predictors of self-reported adherence to antihypertensive medicines: a multinational, cross-sectional survey. Value Health. 2015;18:206-16 pubmed publisher
    ..These should be targets for interventions for improving adherence, as should an appreciation of differences among the countries in which they are being delivered. ..
  9. Jenkinson M, Javadpour M, Haylock B, Young B, Gillard H, Vinten J, et al. The ROAM/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial. Trials. 2015;16:519 pubmed publisher
    ..The results of this study will be used to inform current neurosurgery and neuro-oncology practice worldwide. ISRCTN71502099 on 19 May 2014. ..

More Information

Publications18

  1. Plumpton C, Brown I, Reuber M, Marson A, Hughes D. Economic evaluation of a behavior-modifying intervention to enhance antiepileptic drug adherence. Epilepsy Behav. 2015;45:180-6 pubmed publisher
    ..However, as with any modeling dependent on limited data on efficacy, there is considerable uncertainty surrounding the clinical effectiveness of the intervention which would require a substantive trial for a more definitive conclusion. ..
  2. Blair J, Gregory J, Hughes D, Ridyard C, Gamble C, McKay A, et al. Study protocol for a randomised controlled trial of insulin delivery by continuous subcutaneous infusion compared to multiple daily injections. Trials. 2015;16:163 pubmed publisher
    ..It will produce data that are meaningful to individual patients and local and national policymakers. The study was registered with the European Clinical Trials Database on 4 November 2010, reference 2010-023792-25. ..
  3. Ridyard C, Dawoud D, Tuersley L, Hughes D. A Systematic Review of Patients' Perspectives on the Subcutaneous Route of Medication Administration. Patient. 2016;9:281-92 pubmed publisher
    ..However, studies were prone to bias, and further robust evidence based on methodologically sound approaches is required to demonstrate how patient choice might translate to improved adherence. ..
  4. Plumpton C, Morris T, Hughes D, White I. Multiple imputation of multiple multi-item scales when a full imputation model is infeasible. BMC Res Notes. 2016;9:45 pubmed publisher
    ..The adaptation of multiple imputation makes better use of available data and can yield substantively different results from simpler techniques. ..
  5. Moore A, Young C, Hughes D. Economic Studies in Motor Neurone Disease: A Systematic Methodological Review. Pharmacoeconomics. 2017;35:397-413 pubmed publisher
    ..Limitations may be addressed through the collection of detailed and representative data from large cohorts of patients. ..
  6. Plumpton C, Roberts D, Pirmohamed M, Hughes D. A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions. Pharmacoeconomics. 2016;34:771-93 pubmed publisher
    ..However, further analyses and (or) availability of robust clinical evidence is necessary to make recommendations for others. ..
  7. Hughes D, Charles J, Dawoud D, Edwards R, Holmes E, Jones C, et al. Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches. Pharmacoeconomics. 2016;34:447-61 pubmed publisher
    ..The limitations of existing approaches are detailed and novel methods introduced. The review is internationally relevant but with a focus towards practice in the UK. ..
  8. Hughes D, Tunnage B, Yeo S. Drugs for exceptionally rare diseases: do they deserve special status for funding?. QJM. 2005;98:829-36 pubmed
    ..Mechanisms are discussed for creating a policy that would reduce geographical inequalities in provision across Europe. ..
  9. Hagemi A, Plumpton C, Hughes D. Renal transplant patients' preference for the supply and delivery of immunosuppressants in Wales: a discrete choice experiment. BMC Nephrol. 2017;18:305 pubmed publisher
    ..A policy for secondary care prescribing and hospital collection of medicines does not align with this preference. ..